Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Overview
- Phase
- Early Phase 1
- Intervention
- Ertugliflozin
- Conditions
- Cardiovascular Diseases
- Sponsor
- Stanford University
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Investigators
Tracey McLaughlin
Professor of Medicine
Stanford University
Eligibility Criteria
Inclusion Criteria
- •patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery or vascular surgery
- •history of Diabetes Mellitus Type 2 currently diet controlled, or on metformin or dpp4 inhibitors
Exclusion Criteria
- •allergy or intolerance to interventional medication
- •currently taking insulin, glp-1 inhibitors, or sulfonylureas
Arms & Interventions
Ertugliflozin (treated tissue)
Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. Tissue samples were incubated with Ertugliflozin to evaluate its effects on lipolysis, inflammation, and gene expression in epicardial, pericardial, and subcutaneous adipose tissues
Intervention: Ertugliflozin
Outcomes
Primary Outcomes
Rate of isoproterenol-stimulated lipolysis to measure metabolic flexibility in epicardial adipose tissue samples.
Time Frame: Time to collect tissue collected during surgery (up to 15 minutes)
Analysis will be performed using Lipolysis Colorimetric Assay and measured by glycerol content on standard curve. Indirect effects of SGLT2i in vivo in epicardial adipose tissue will be compared to Glipizide by measuring rate of lipolysis, or breakdown of adipose in to free fatty acids.
Secondary Outcomes
- Average insulin mediated glucose uptake (IMGU) to measure insulin sensitivity in epicardial adipose tissue samples.(Time to collect tissue collected during surgery (up to 15 minutes))
- Characterization of the inflammatory cytokine expression profile in epicardial adipose tissue samples.(Time to collect tissue collected during surgery (up to 15 minutes))
- Distribution of adipose cell size in epicardial tissue.(Time to collect tissue collected during surgery (up to 15 minutes))